RESUMO
The paper examines the different perceptions of risk associated with anesthesia systems from the viewpoint of the product manufacturer and the caregiver. Only a little research has been done with regard to the impact of perception of risk on patient safety in anesthesia. The role of the manufacturer in mitigating the perception of risk will be central for the work. The risk will be examined as the probability of negative occurrences based on the Medical Device Reportable (MDR) events for 2016 and 2017 and it will be examined how the caregiver perceives and manages these risks when delivering anesthesia. Analysis of the manufacturer's public Medical Device Reportable events data will be performed in the US market and will represent the actual risk achieved; this review will provide a perspective on how the risk is perceived and managed by the caregiver when delivering anesthesia. The goals of the paper are to highlight how the role of the manufacturers can have an impact on the reduction of perception of risk, increasing patient safety, and showing how the perception of risk is usually magnified by the hospital personnel.
Assuntos
Anestesia/normas , Cuidadores/normas , Indústria Manufatureira/normas , Exposição Ocupacional/normas , Segurança do Paciente/normas , Percepção , Anestesia/efeitos adversos , Cuidadores/psicologia , Humanos , Indústria Manufatureira/instrumentação , Exposição Ocupacional/prevenção & controleRESUMO
Analogues of the kappa (kappa) opioid receptor agonist, ICI 199441, were prepared. Ki values for these analogues at the cloned human kappa opioid receptor ranged from 0.058 to 25 nM. Trifluoromethylaryl derivatives were potent analgesics when administered subcutaneously in the rat and were more peripherally restricted than the parent compound, ICI 199441.
Assuntos
Acetamidas/farmacologia , Analgésicos Opioides/farmacologia , Pirrolidinas/farmacologia , Receptores Opioides kappa/agonistas , Acetamidas/química , Analgésicos Opioides/química , Animais , Estrutura Molecular , Pirrolidinas/química , RatosRESUMO
A series of novel aminodiol inhibitors of HIV protease based on the lead compound 1 with structural modifications at P1' were synthesized in order to reduce the cytotoxicity of 1. We have observed a high degree of correlation between the lipophilicity and cytotoxicity of this series of inhibitors. It was found that appropriate substitution at the para position of the P1' phenyl group of 1 resulted in the identification of equipotent (both against the enzyme and in cell culture) compounds (10l, 10m, 10n, and 15c) which possess significantly decreased cytotoxicity.
